Key result
High-risk individuals with combined impaired fasting glucose (110-125 mg/dl) and elevated HbA1c (6.0%-6.4%) had a significantly higher risk of developing type 2 diabetes (HR 4.56) compared to those with normal glycemic levels.
Why the study?
The incidences of diabetes and diabetic retinopathy in Thai high-risk individuals with prediabetes had not been identified.
Do higher degrees of dysglycemia (elevated FPG and HbA1c) predict the risk of incident type 2 diabetes and diabetic retinopathy in a high-risk population with prediabetes?
Cohort (n=8,977)
No
Do higher degrees of dysglycemia (elevated FPG and HbA1c) predict the risk of incident type 2 diabetes and diabetic retinopathy in a high-risk population with prediabetes?
Hazard Ratio: 4.56 (95% CI 3.39–6.15)
Absolute Event Rate: 48.5% vs 16%
p-value: p=<0.001
In a high-risk Thai population, combined elevations in fasting plasma glucose and HbA1c strongly predict progression to type 2 diabetes and diabetic retinopathy, highlighting the need for aggressive lifestyle and pharmacological management in this subgroup.
Alerts to DR risk in Thai prediabetes; leaves open prospective validation of FPG/HbA1c thresholds.
Introduction: The incidences of diabetes and diabetic retinopathy (DR) in Thai high-risk individuals with prediabetes have not been identified. This study compared diabetes and DR incidences among people at risk with different glycemic levels, using fasting plasma glucose (FPG) and hemoglobin A1C (HbA1c). Materials and methods: A historical cohort study estimating risk of type 2 diabetes and DR was conducted among outpatients, using FPG and HbA1c measurements at recruitment and monitored for ≥5 years. High-risk participants (defined as having metabolic syndrome or atherosclerotic cardiovascular disease) were categorized by glycemic level into 4 groups: 1) impaired fasting glucose (IFG)-/HbA1c- (FPG <110 mg/dl; HbA1c < 6.0%); 2) IFG+/HbA1c- (FPG 110–125 mg/dl; HbA1c < 6.0%); 3) IFG-/HbA1c+ (FPG <110 mg/dl; HbA1c 6.0%–6.4%); and 4) IFG+/HbA1c+ (FPG 110–125 mg/dl; HbA1c 6.0%–6.4%). The incidences of type 2 diabetes mellitus (T2DM) and DR were obtained and estimated using Kaplan-Meier analysis. Cox regression models explored hazard ratios (HRs). Results: We recruited 8,977 people at risk (metabolic syndrome, 89.9%; atherosclerotic cardiovascular disease, 16.9%). The baseline cohort consisted of 1) IFG-/HbA1c- ( n = 4,221; 47.0%); 2) IFG+/HbA1c- ( n = 1,274; 14.2%); 3) IFG-/HbA1c+ ( n = 2,151; 24.0%); and 4) IFG+/HbA1c+ ( n = 1,331; 14.8%). Their 5-year T2DM incidences were 16.0%, 26.4%, 30.8%, and 48.5% ( p < 0.001). The median DR follow-up was 7.8 years (interquartile range, 7.0–8.4 years). The DR incidences were 0.50, 0.63, 1.44, and 2.68/1,000 person-years ( p < 0.001) for IFG-/HbA1c-, IFG+/HbA1c-, IFG-/HbA1c+, and IFG+/HbA1c+, respectively. Compared with IFG-/HbA1c-, the multivariable-adjusted HRs (95% CI) for incident diabetes were 1.94 (1.34–2.80), 2.45 (1.83–3.29), and 4.56 (3.39–6.15) for IFG+/HbA1c-, IFG-/HbA1c+, and IFG+/HbA1c+, respectively. As for incident DR, the corresponding HRs were 0.67 (0.08–5.76), 4.74 (1.69–13.31), and 5.46 (1.82–16.39), respectively. Conclusion: The 5-year incidence of T2DM in Thai high-risk participants with prediabetes was very high. The incidences of diabetes and DR significantly increased with higher degrees of dysglycemia. High-risk people with FPG 110–125 mg/dl and HbA1c 6.0%–6.4% were more likely to develop T2DM and DR. Such individuals should receive priority lifestyle and pharmacological management.
No takes yet. Share an insight, caveat, or question.
Washirasaksiri et al. (2022) conducted a cohort in Prediabetes (n=8,977). Combined impaired fasting glucose (110-125 mg/dl) and elevated HbA1c (6.0%-6.4%) vs. Normal fasting glucose (<110 mg/dl) and HbA1c (<6.0%) was evaluated on 5-year incidence of type 2 diabetes mellitus (HR 4.56, 95% CI 3.39-6.15, p=<0.001). High-risk individuals with combined impaired fasting glucose (110-125 mg/dl) and elevated HbA1c (6.0%-6.4%) had a significantly higher risk of developing type 2 diabetes (HR 4.56) compared to those with normal glycemic levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: